当前位置:首页 - 行情中心 - 华兰疫苗(301207) - 财务分析 - 现金流量表

华兰疫苗

(301207)

  

流通市值:113.28亿  总市值:113.35亿
流通股本:6.01亿   总股本:6.01亿

现金流量表

报告期2025-09-302025-06-302025-03-312024-12-31
公司类型通用通用通用通用
一、经营活动产生的现金流量:
  销售商品、提供劳务收到的现金840,417,243.67545,178,790.44214,904,356.361,802,151,946.84
  收到其他与经营活动有关的现金25,073,444.1912,574,162.779,333,385.3930,813,985.5
  经营活动现金流入小计865,490,687.86557,752,953.21224,237,741.751,832,965,932.34
  购买商品、接受劳务支付的现金125,460,323.9773,935,589.2156,756,914.31252,503,004.83
  支付给职工以及为职工支付的现金72,369,987.450,728,557.3330,260,391.7395,535,970.3
  支付的各项税费34,523,717.0814,211,098.111,804,163.47151,496,897.11
  支付其他与经营活动有关的现金451,172,541.16313,099,535.45128,003,898.05865,388,617.62
  经营活动现金流出小计683,526,569.61451,974,780.09226,825,367.561,364,924,489.86
  经营活动产生的现金流量净额181,964,118.25105,778,173.12-2,587,625.81468,041,442.48
二、投资活动产生的现金流量:
  收回投资收到的现金6,174,057,527.945,153,077,109.943,448,841,058.2719,343,331,772.14
  取得投资收益收到的现金88,582,502.9348,295,924.1236,833,321.3385,234,155.13
  处置固定资产、无形资产和其他长期资产收回的现金净额40,000-043,000
  投资活动现金流入小计6,262,680,030.875,201,373,034.063,485,674,379.619,428,608,927.27
  购建固定资产、无形资产和其他长期资产支付的现金4,196,790.734,450,229.592,104,640.7251,595,885.69
  投资支付的现金5,769,408,615.44,984,408,615.43,583,226,064.2619,438,092,900.5
  投资活动现金流出小计5,773,605,406.134,988,858,844.993,585,330,704.9819,489,688,786.19
  投资活动产生的现金流量净额489,074,624.74212,514,189.07-99,656,325.38-61,079,858.92
三、筹资活动产生的现金流量:
  吸收投资收到的现金---16,281,000
  筹资活动现金流入平衡项目---0
  筹资活动现金流入小计---16,281,000
  偿还债务支付的现金300,000,000300,000,000--
  分配股利、利润或偿付利息支付的现金140,093,339.9559,093,339.9530,660,000.01334,316,500.02
  支付其他与筹资活动有关的现金---106,786,852.51
  筹资活动现金流出小计440,093,339.95359,093,339.9530,660,000.01441,103,352.53
  筹资活动产生的现金流量净额-440,093,339.95-359,093,339.95-30,660,000.01-424,822,352.53
四、汇率变动对现金及现金等价物的影响155,717.47170,007.4255,928.01-84,323.07
五、现金及现金等价物净增加额231,101,120.51-40,630,970.34-132,848,023.19-17,945,092.04
  加:期初现金及现金等价物余额623,035,019.91623,035,019.91623,035,019.91640,980,111.95
  期末现金及现金等价物余额854,136,140.42582,404,049.57490,186,996.72623,035,019.91
补充资料:
  净利润-20,797,156.8-205,515,315.75
  资产减值准备--12,277,453.7-74,225,065.72
  固定资产和投资性房地产折旧-70,079,889.34-139,716,352.2
  其中:固定资产折旧、油气资产折耗、生产性生物资产折旧-70,079,889.34-139,716,352.2
  无形资产摊销-397,393.71-664,579.5
  长期待摊费用摊销-0-1,669,257.93
  处置固定资产、无形资产和其他长期资产的损失-0-140,144.03
  固定资产报废损失-4,139.15-241,788.14
  公允价值变动损失--10,279,395.19--24,300,582.77
  财务费用-2,585,223.01-6,040,684.3
  投资损失--39,067,003.76--76,072,994.64
  递延所得税--9,595,212.86-8,821,031.26
  其中:递延所得税资产减少--9,787,104.34-5,241,954.74
    递延所得税负债增加-191,891.48-3,579,076.52
  存货的减少--159,904,129.76--97,315,504.69
  经营性应收项目的减少-568,098,449.84-884,472,870.07
  经营性应付项目的增加--279,390,559.53--642,067,069.65
  其他-3,591,465.83--4,340,367.76
  现金的期末余额-582,404,049.57-623,035,019.91
  减:现金的期初余额-623,035,019.91-640,980,111.95
  加:现金等价物的期末余额-0--
  减:现金等价物的期初余额-0--
  现金及现金等价物的净增加额--40,630,970.34--17,945,092.04
公告日期2025-10-302025-08-282025-04-282025-03-29
审计意见(境内)标准无保留意见
TOP↑